Lipoprotein subfraction concentrations and size using NMR after 4 months according to treatment group (VLDL-<i>P</i>; LDL-<i>P</i>; HDL-<i>P</i>; Lipoprotein size).

<p>Data are presented as median (interquartile range). <i>P</i>-values from unpaired—tests. <i>P</i>-value ≤ 0.0063 placebo vs. Metformin group.</p

Novel SNVs/Genes associated with BP traits in Multi-ancestry meta-analysis in combined Stage 1 and Stage 2.

<p>Novel SNVs/Genes associated with BP traits in Multi-ancestry meta-analysis in combined Stage 1 and Stage 2.</p

Identification of four independent LD blocks in the 8p23.1 region <i>(~3</i>.<i>3 MBs</i>).

<p>Identification of four independent LD blocks in the 8p23.1 region <i>(~3</i>.<i>3 MBs</i>).</p

Potential novel SNVs/Genes associated with BP traits in African ancestry.

<p>Potential novel SNVs/Genes associated with BP traits in African ancestry.</p

Novel SNVs/Genes associated with BP traits from correlated meta-analysis in European ancestry in Stage 1.

<p>Novel SNVs/Genes associated with BP traits from correlated meta-analysis in European ancestry in Stage 1.</p

Novel SNVs/Genes associated with BP traits in European ancestry.

<p>Novel SNVs/Genes associated with BP traits in European ancestry.</p

Novel SNVs/Genes associated with BP traits in European ancestry.

<p>Novel SNVs/Genes associated with BP traits in European ancestry.</p